Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
octavalent HPV L1 VLP vaccine
- Development stage
- Phase 2
- Lead developer
- Merck
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
A prophylactic, protein subunit HPV vaccine composed of L1 capsid protein virus-like particles (VLPs) from eight human papillomavirus types, designed to induce type-specific neutralizing antibodies and prevent infection and HPV-related disease. L1 VLP vaccines work by presenting conformational epitopes that elicit robust humoral immunity without containing viral DNA. Compared with licensed quadrivalent (HPV6/11/16/18) and nonavalent (HPV6/11/16/18/31/33/45/52/58) vaccines, an octavalent composition is not a standard, widely referenced formulation in current literature and regulatory documents; most advanced multivalent candidates are nonavalent or higher-valent (e.g., 11-valent) L1 VLP vaccines. As such, this appears to refer to a hypothetical or investigational naming rather than an established product. The closest established products are quadrivalent Gardasil and nonavalent 9vHPV, both recombinant L1 VLP vaccines using alum-based adjuvants and proven to be safe and effective.
- Other names
- 8-valent HPV L1 virus-like particle vaccineoctavalent HPV vaccine8vHPV
02
Targets
HPV L1 (Human papillomavirus L1 capsid protein)
Beyond the preview
Go deeper on octavalent HPV L1 VLP vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on octavalent HPV L1 VLP vaccine.